Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 2,537 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Like Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution

NCT00776555
View directory record Official record
Conditions
Healthy
Interventions
Lisdexamfetamine Dimesylate, Racemic mixture of dextroamphetamine and lisdexamfetamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 25 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Banning Menthol Flavorant on Cigarette and E-Cigarette Use

NCT03402243
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Menthol ban on cigarettes, Menthol ban on cigarettes and e-cigarettes, No menthol ban
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Not applicable Interventional Results available

Pediatric Laser Acupuncture and Renal Biopsy

NCT01879826
View directory record Official record
Conditions
Pain, Anxiety
Interventions
Aculaser applied to kidney points, Aculaser applied to sham points
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
7 Years to 25 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 22, 2026, 5:29 AM EDT
Recruiting Not applicable Interventional

A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease

NCT06647615
View directory record Official record
Conditions
Crohn's Disease, Abdominal Pain (AP)
Interventions
VR headset
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 22, 2026, 5:29 AM EDT
Active, not recruiting Phase 4 Interventional

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

NCT06801015
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Tirzepatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

Dimethyl Fumarate for Obstructive Sleep Apnea

NCT02438137
View directory record Official record
Conditions
Obstructive Sleep Apnea, OSA, Sleep Apnea
Interventions
Dimethyl fumarate, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.

NCT07575906
View directory record Official record
Conditions
Healthy
Interventions
PF-08057418, Placebo (A placebo does not have any medicine in it but looks just like the medicine being studied.)
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

NCT02078674
View directory record Official record
Conditions
Influenza (Pandemic)
Interventions
Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 64 Years
Enrollment
610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
5
States / cities
Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 22, 2026, 5:29 AM EDT
Completed No phase listed Observational

Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

NCT07088718
View directory record Official record
Conditions
Type 2 Diabetes, Major Adverse Cardiac Events, Cardiovascular (CV) Risk
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
44,671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

NCT04657003
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
938 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 22, 2026, 5:29 AM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

NCT06980623
View directory record Official record
Conditions
Type 2 Diabetes, Heart Failure
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
26,000 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

NCT01413542
View directory record Official record
Conditions
Hypertension, Diabetes Type 2
Interventions
Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide in Participants With Impaired Liver Function

NCT03940742
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Tustin, California • Orlando, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV

NCT05828095
View directory record Official record
Conditions
HIV-1-infection
Interventions
INO-6160, 2 mg, Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Not applicable Interventional

Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study

NCT07487701
View directory record Official record
Conditions
Migraine
Interventions
Nerivio REN device
Device
Lead sponsor
Theranica
Industry
Eligibility
8 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Not applicable Interventional Results available

Perineural Local Anesthetic Administration With a Continuous Infusion Versus Automatic Intermittent Boluses

NCT04458467
View directory record Official record
Conditions
Pain, Acute, Anesthesia, Local, Trauma Injury
Interventions
Continuous Infusion, Automated Intermittent Boluses
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 22, 2026, 5:29 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

NCT07284875
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Ribupatide, Placebo
Drug
Lead sponsor
Kailera
Industry
Eligibility
18 Years and older
Enrollment
2,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 5:29 AM EDT
Completed No phase listed Observational

Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention

NCT03662295
View directory record Official record
Conditions
Migraine Disorders, Aphasia
Interventions
Language treatment
Behavioral
Lead sponsor
Quality Living, Inc.
Other
Eligibility
19 Years to 65 Years
Enrollment
1 participant
Timeline
2018 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 22, 2026, 5:29 AM EDT
Terminated Phase 2 Interventional Results available

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

NCT05579977
View directory record Official record
Conditions
Diabetes Mellitus, Obesity
Interventions
PF-07081532, Placebo, Rybelsus
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
39
States / cities
Centreville, Alabama • Anaheim, California • Canoga Park, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Brown Seaweed as a Breast Cancer Preventive

NCT01204957
View directory record Official record
Conditions
Breast Cancer
Interventions
Seaweed and Soy Protein, Placebo and Soy Protein
Dietary Supplement
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 1999
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Exclusion Criteria in a University Population

NCT01472536
View directory record Official record
Conditions
Influenza
Interventions
Sequestration
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia

NCT05655819
View directory record Official record
Conditions
Functional Dyspepsia
Interventions
Glutamine, Placebo
Drug
Lead sponsor
David J. Cangemi
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 22, 2026, 5:29 AM EDT
Terminated Phase 2 Interventional

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

NCT03645928
View directory record Official record
Conditions
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Interventions
Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed
Biological · Drug
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 22, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Marathon and Enduron Polyethylene at Long-Term Follow-up

NCT02508428
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
Interventions
Hip Replacement with crosslinked Marathon polyethylene, Hip Replacement with noncrosslinked Enduron polyethylene
Device
Lead sponsor
Anderson Orthopaedic Research Institute
Other
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2017
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 22, 2026, 5:29 AM EDT